Acute Rheumatic Fever and Rheumatic Heart Disease in Indigenous Populations

Pediatric Clinics of North America

Volumn 56, Issue 6, 2009, Pages 1401-1419

  Steer, Andrew C ^a,b   Carapetis, Jonathan R ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

Acute rheumatic fever; Rheumatic heart disease; Streptococcus pyogenes

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; BENZATHINE PENICILLIN; C REACTIVE PROTEIN; CARBAMAZEPINE; GLUCOCORTICOID; HALOPERIDOL; IMMUNOGLOBULIN; M PROTEIN; N ACETYLGLUCOSAMINE; NAPROXEN; PENICILLIN V; STREPTOCOCCUS VACCINE; VALPROIC ACID; VASCULAR CELL ADHESION MOLECULE 1;

ANAMNESIS; ANTIBODY TITER; ARTHRALGIA; ARTHRITIS; BACTERIUM CULTURE; CARDITIS; CHILD; CHOREA; CLINICAL EXAMINATION; CROWDING; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENVIRONMENTAL FACTOR; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEVER; GENETIC SUSCEPTIBILITY; HEALTH CARE ACCESS; HEALTH EDUCATION; HEALTH PROMOTION; HUMAN; IMMUNOPATHOGENESIS; IMPETIGO; INDIGENOUS PEOPLE; INFECTION SENSITIVITY; LIVER DISEASE; PATHOGENESIS; PATIENT COMPLIANCE; PHARYNGITIS; POLYARTHRITIS; PR INTERVAL; PREVALENCE; PYODERMA; REVIEW; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; SINGLE DRUG DOSE; SOCIAL ASPECT; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; SUBCUTANEOUS NODULE; TREATMENT DURATION;

ACUTE-PHASE PROTEINS; ALASKA; ARTHRITIS; AUSTRALIA; BLOOD SEDIMENTATION; CHILD; CHOREA; DIAGNOSIS, DIFFERENTIAL; FEVER; HUMANS; MYOCARDITIS; NEW ZEALAND; POPULATION GROUPS; PREVALENCE; PRIMARY PREVENTION; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; SECONDARY PREVENTION; SOCIAL JUSTICE; UNITED STATES;

EID: 71949117688     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2009.09.011     Document Type: Review

References (106)

1. Sanyal S.K., Berry A.M., Duggal S., et al. Sequelae of the initial attack of acute rheumatic fever in children from north India. A prospective 5-year follow-up study. Circulation 65 (1982) 375-379
2. Sanyal S.K., Thapar M.K., Ahmed S.H., et al. The initial attack of acute rheumatic fever during childhood in north India; a prospective study of the clinical profile. Circulation 49 (1974) 7-12
3. Steer A.C., Kado J., Jenney A.W., et al. Acute rheumatic fever and rheumatic heart disease in Fiji: prospective surveillance, 2005-2007. Med J Aust 190 (2009) 133-135
4. Brown A., McDonald M.I., and Calma T. Rheumatic fever and social justice. Med J Aust 186 (2007) 557-558
5. Carapetis J.R., Steer A.C., Mulholland E.K., et al. The global burden of group A streptococcal diseases. Lancet Infect Dis 5 (2005) 685-694
6. Quinn R.W. Comprehensive review of morbidity and mortality trends for rheumatic fever, streptococcal disease, and scarlet fever: the decline of rheumatic fever. Rev Infect Dis 11 (1989) 928-953
7. Carapetis J.R. Rheumatic heart disease in Asia. Circulation 118 (2008) 2748-2753
8. Neutze J.M. Rheumatic fever and rheumatic heart disease in the western Pacific region. N Z Med J 101 (1988) 404-406
9. Chun L.T., Reddy D.V., Yim G.K., et al. Acute rheumatic fever in Hawaii: 1966 to 1988. Hawaii Med J 51 (1992) 206-211
10. Carapetis J.R., Wolff D.R., and Currie B.J. Acute rheumatic fever and rheumatic heart disease in the top end of Australia's Northern Territory. Med J Aust 164 (1996) 146-149
11. Jaine R., Baker M., and Venugopal K. Epidemiology of acute rheumatic fever in New Zealand 1996-2005. J Paediatr Child Health 44 (2008) 564-571
12. National Heart Foundation of Australia (RF/RHD guideline development working group), and the Cardiac Society of Australia and New Zealand. Diagnosis and management of acute rheumatic fever and rheumatic heart disease in Australia - an evidence-based review (2006), National Heart Foundation of Australia, Canberra
13. National Heart Foundation of New Zealand, and Cardiac Society of Australia and New Zealand. Evidence-based, best practice New Zealand guidelines for rheumatic fever 1. Diagnosis, management and secondary prevention (2006), National Heart Foundation of New Zealand, Auckland
14. Steer A.C., Carapetis J.R., Nolan T.M., et al. Systematic review of rheumatic heart disease prevalence in children in developing countries: the role of environmental factors. J Paediatr Child Health 38 (2002) 229-234
15. Gordis L., Lilienfeld A., and Rodriguez R. Studies in the epidemiology and preventability of rheumatic fever. II. Socio-economic factors and the incidence of acute attacks. J Chronic Dis 21 (1969) 655-666
16. Wannamaker L.W. The epidemiology of streptococcal infections. In: McCarty M. (Ed). Streptococcal infections (1954), Columbia University Press, New York
17. Longo-Mbenza B., Bayekula M., Ngiyulu R., et al. Survey of rheumatic heart disease in school children of Kinshasa town. Int J Cardiol 63 (1998) 287-294
18. McDonald M.I., Towers R.J., Andrews R.M., et al. Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian Aboriginal communities where acute rheumatic fever is hyperendemic. Clin Infect Dis 43 (2006) 683-689
19. Carapetis J.R., Currie B.J., and Good M.F. Towards understanding the pathogenesis of rheumatic fever. Scand J Rheumatol 25 (1996) 127-131
20. Carapetis J.R., Currie B.J., and Mathews J.D. Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population?. Epidemiol Infect 124 (2000) 239-244
21. Bryant P.A., Robbins-Browne R., Carapetis J.R., et al. Some of the people, some of the time. Susceptibility to acute rheumatic fever. Circulation 119 (2009) 742-753
22. Rammelkamp C.H., Wannamaker L.W., and Denny F.W. The epidemiology and prevention of rheumatic fever. 1952. Bull N Y Acad Med 74 (1997) 119-133
23. Holmes M.C., and Rubbo S.D. A study of rheumatic fever and streptococcal infection in different social groups in Melbourne. J Hyg (Lond) 51 (1953) 450-457
24. Harrington Z., Visvanathan K., Skinner N.A., et al. B-cell antigen D8/17 is a marker of rheumatic fever susceptibility in Aboriginal Australians and can be tested in remote settings. Med J Aust 184 (2006) 507-510
25. Khanna A.K., Buskirk D.R., Williams Jr. R.C., et al. Presence of a non-HLA B cell antigen in rheumatic fever patients and their families as defined by a monoclonal antibody. J Clin Invest 83 (1989) 1710-1716
26. Harel L., Zeharia A., Kodman Y., et al. Presence of the d8/17 B-cell marker in children with rheumatic fever in Israel. Clin Genet 61 (2002) 293-298
27. Kaur S., Kumar D., Grover A., et al. Ethnic differences in expression of susceptibility marker(s) in rheumatic fever/rheumatic heart disease patients. Int J Cardiol 64 (1998) 9-14
28. Taneja V., Mehra N.K., Reddy K.S., et al. HLA-DR/DQ antigens and reactivity to B cell alloantigen D8/17 in Indian patients with rheumatic heart disease. Circulation 80 (1989) 335-340
29. Bisno A.L., Pearce I.A., Wall H.P., et al. Contrasting epidemiology of acute rheumatic fever and acute glomerulonephritis. N Engl J Med 283 (1970) 561-565
30. Carapetis J.R., and Currie B.J. Group A streptococcus, pyoderma, and rheumatic fever. Lancet 347 (1996) 1271-1272
31. Martin D.R. Rheumatogenic and nephritogenic group A streptococci. Myth or reality? An opening lecture. Adv Exp Med Biol 418 (1997) 21-27
32. Bessen D.E., Carapetis J.R., Beall B., et al. Contrasting molecular epidemiology of group A streptococci causing tropical and nontropical infections of the skin and throat. J Infect Dis 182 (2000) 1109-1116
33. Steer A.C., Magor G., Jenney A.W., et al. emm and C-repeat region molecular typing of beta-hemolytic streptococci in a tropical country: implications for vaccine development. J Clin Microbiol 47 8 (2009) 2502-2509
34. Martin D.R., Voss L.M., Walker S.J., et al. Acute rheumatic fever in Auckland, New Zealand: spectrum of associated group A streptococci different from expected. Pediatr Infect Dis J 13 (1994) 264-269
35. McDonald M., Currie B.J., and Carapetis J.R. Acute rheumatic fever: a chink in the chain that links the heart to the throat?. Lancet Infect Dis 4 (2004) 240-245
36. Steer A.C., Tikoduadua L.V., Manalac E.M., et al. Validation of an Integrated Management of Childhood Illness algorithm for the management of common skin conditions in Fiji. Bull World Health Organ 87 (2009) 173-179
37. Lawrence G.W., Leafasia J., Sheridan J., et al. Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. Bull World Health Organ 83 (2005) 34-42
38. Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. JAMA 268 (1992) 2069-2073
39. Jones T.D. The diagnosis of rheumatic fever. JAMA 126 (1944) 481-484
40. Rutstein D.D., Bauer W., Dorfman A., et al. Jones Criteria (modified) for guidance in the diagnosis of rheumatic fever; report of the Committee on Standards and Criteria for programs of care. Circulation 13 (1956) 617-620
41. Committee of Rheumatic Fever and Bacterial Endocarditis of the American Heart Association: Jones Criteria (revised) for guidance in the diagnosis of rheumatic fever. Circulation 69 (1984) 204A-208A
42. Stollerman G.H., Markowitz M., Taranta A., et al. Committee report: Jones Criteria (revised) for guidance in the diagnosis of rheumatic fever. Circulation 32 (1965) 664-668
43. Pereira B.A.F., da Silva N.A., Andrade L.E.C., et al. Jones Criteria and underdiagnosis of rheumatic fever. Indian J Pediatr 74 (2007) 117-121
44. Cherian G. Acute rheumatic fever-the Jones Criteria: a review and a case for polyarthralgia. J Assoc Physicians India 27 (1979) 453-457
45. Padmavati S., and Gupta V. Reappraisal of the Jones Criteria: the Indian experience. N Z Med J 101 (1988) 391-392
46. Carapetis J.R., and Currie B.J. Rheumatic fever in a high incidence population: the importance of monoarthritis and low grade fever. Arch Dis Child 85 (2001) 223-227
47. Mataika R., Carapetis J.R., Kado J., et al. Acute rheumatic fever: an important differential diagnosis of septic arthritis. J Trop Pediatr 54 (2008) 205-207
48. Harlan G.A., Tani L.Y., and Byington C.L. Rheumatic fever presenting as monoarticular arthritis. Pediatr Infect Dis J 25 (2006) 743-746
49. Wilson E., Wilson N., Voss L., et al. Monoarthritis in rheumatic fever?. Pediatr Infect Dis J 26 (2007) 369-370
50. Vasan R.S., Shrivastava S., Vijayakumar M., et al. Echocardiographic evaluation of patients with acute rheumatic fever and rheumatic carditis. Circulation 94 (1996) 73-82
51. Tubridy-Clark M., and Carapetis J.R. Subclinical carditis in rheumatic fever: a systematic review. Int J Cardiol 119 (2007) 54-58
52. Narula J., and Kaplan E.L. Echocardiographic diagnosis of rheumatic fever. Lancet 2001 (2000) 358
53. Wilson N.J., and Neutze J.M. Echocardiographic diagnosis of subclinical carditis in acute rheumatic fever. Int J Cardiol 50 (1995) 1-6
54. Veasy L.G. Time to take soundings in acute rheumatic fever. Lancet 357 (2001) 1994-1995
55. Marijon E., Ou P., Celermajer D.S., et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 357 (2007) 470-476
56. Carapetis J.R., Hardy M., Fakakovikaetau T., et al. High prevalence of rheumatic heart disease in Tongan school children, and evaluation of a screening protocol using portable echocardiography. Nat Clin Pract Cardiovasc Med 5 (2008) 411-417
57. Working Group on Pediatric Acute Rheumatic Fever and Cardiology Chapter of Indian Academy of Pediatrics. Consensus guidelines on pediatric acute rheumatic fever and rheumatic heart disease. Indian Pediatr 45 (2008) 565-573
58. Rheumatic fever and rheumatic heart disease: report of a WHO Expert Consultation Geneva (2004), World Health Organization, Geneva
59. Hashkes P.J., Tauber T., Somekh E., et al. Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial. J Pediatr 143 (2003) 399-401
60. Feinstein A.R., Spagnuolo M., and Gill F.A. The rebound phenomenon in acute rheumatic fever. I. Incidence and significance. Yale J Biol Med 33 (1961) 259-278
61. Holt K.S. The rebound phenomenon in acute rheumatic fever. Arch Dis Child 31 (1956) 444-451
62. Carapetis J.R., Kilburn C.J., MacDonald K.T., et al. Ten-year follow up of a cohort with rheumatic heart disease (RHD). Aust N Z J Med 27 (1997) 691-697
63. Rheumatic Fever Working Party. The natural history of rheumatic fever and rheumatic heart disease: ten-year report of a cooperative clinical trial of ACTH, cortisone, and aspirin. Circulation 32 (1965) 457-476
64. Bywaters E.G.L., and Thomas G.T. Bed rest, salicylates and steroid in rheumatic fever. BMJ 1 (1961) 1628-1634
65. Dorfman A., Gross J.I., and Lorincz A.E. The treatment of acute rheumatic fever. Pediatrics 27 (1961) 692-706
66. Illingworth R.S., Lorber J., and Holt K.S. Acute rheumatic fever in children: a comparison of six forms of treatment in 200 cases. Lancet 273 (1957) 653-659
67. Cilliers A.M., Manyemba J., and Saloojee H. Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev 2 (2003) CD003176
68. Czoniczer G., Amezcua F., Pelargonio S., et al. Therapy of severe rheumatic carditis. Comparison of adrenocortical steroids and aspirin. Circulation 29 (1964) 813-819
69. Albert D.A., Harel L., and Karrison T. The treatment of rheumatic carditis: a review and meta-analysis. Medicine (Baltimore) 74 (1995) 1-12
70. Thatai D., and Turi Z.G. Current guidelines for the treatment of patients with rheumatic fever. Drugs 57 (1999) 545-555
71. Lessof M.H., and Bywaters E.G. The duration of chorea. Br Med J 1 (1956) 1520-1523
72. Carapetis J.R., and Currie B.J. Rheumatic chorea in northern Australia: a clinical and epidemiological study. Arch Dis Child 80 (1999) 353-358
73. Pena J., Mora E., Cardozo J., et al. Comparison of the efficacy of carbamazepine, haloperidol and valproic acid in the treatment of children with Sydenham's chorea: clinical follow-up of 18 patients. Arq Neuropsiquiatr 60 (2002) 374-377
74. Voss L.M., Wilson N.J., Neutze J.M., et al. Intravenous immunoglobulin in acute rheumatic fever: a randomized controlled trial. Circulation 103 (2001) 401-406
75. Veasy L.G., Wiedmeier S.E., Orsmond G.S., et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med 316 (1987) 421-427
76. Gerber M.A., Baltimore R.S., Eaton C.B., et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 119 (2009) 1541-1551
77. Del Mar C.B., Glasziou P.P., and Spinks A.B. Antibiotics for sore throat. Cochrane Database Syst Rev 4 (2000) CD000023
78. Denny F., Wannamaker L., Brink W., et al. Prevention of rheumatic fever; treatment of preceding streptococci infection. JAMA 143 (1950) 151-153
79. Robertson K.A., Volmink J.A., and Mayosi B.M. Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. BMC Cardiovasc Disord 31 (2005) 11
80. Stollerman G.H., Rusoff J.H., and Hirschfeld I. Prophylaxis against group A streptococci in rheumatic fever; the use of single monthly injections of benzathine penicillin G. N Engl J Med 252 (1955) 787-792
81. Tompkins D.G., Boxerbaum B., and Liebman J. Long-term prognosis of rheumatic fever patients receiving regular intramuscular benzathine penicillin. Circulation 45 (1972) 543-551
82. Michaud C., Rammohan R., and Narula J. Cost-effectiveness analysis of intervention strategies for reduction of the burden of rheumatic heart disease. In: Narula J., Virmani R., Reddy K.S., et al. (Eds). Rheumatic fever (1999), American Registry of Pathology, Washington, DC 485-497
83. Carapetis J.R. Rheumatic heart disease in developing countries. N Engl J Med 357 (2007) 439-441
84. Strasser T. Cost-effective control of rheumatic fever in the community. Health Policy 5 (1985) 159-164
85. Manyemba J., and Mayosi B.M. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev 3 (2002) CD002227
86. Lue H.C., Wu M.H., Hsieh K.H., et al. Rheumatic fever recurrences: controlled study of 3-week versus 4-week benzathine penicillin prevention programs. J Pediatr 108 (1986) 299-304
87. Lue H.C., Wu M.H., Wang J.K., et al. Long-term outcome of patients with rheumatic fever receiving benzathine penicillin G prophylaxis every three weeks versus every four weeks. J Pediatr 125 (1994) 812-816
88. McDonald M., Brown A., Noonan S., et al. Preventing rheumatic fever: the role of register based programmes. Heart 91 (2005) 1131-1133
89. Bach J.F., Chalons S., Forier E., et al. 10-year educational programme aimed at rheumatic fever in two French Caribbean islands. Lancet 347 (1996) 644-648
90. Carapetis J.R. Pediatric rheumatic heart disease in the developing world: echocardiographic versus clinical screening. Nat Clin Pract Cardiovasc Med 5 (2008) 74-75
91. Bisno A.L., Rubin F.A., Cleary P.P., et al. Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles-report of a National Institute of Allergy and Infectious Diseases workshop. Clin Infect Dis 41 (2005) 1150-1156
92. Group A streptococcal vaccine development: current status and issues of relevance to less developed countries (2005), World Health Organization, Department of Child and Adolescent Health and Development, Geneva
93. McNeil SA, Halperin SA, Langley JB, et al. A double-blinded, randomized, controlled phase II trial of the safety and immunogenicity of a 26 valent group A streptococcus vaccine in healthy adults. The XVIth Lancefield International Symposium on Streptococci and Streptococcal Diseases; 2005:25-29. September 2005; Palm Cove, Australia.
94. Steer A.C., Jenney A.W.J., Kado J., et al. Invasive group A streptococcal disease in Fiji: prospective surveillance 2005-2007. Emerg Infect Dis 15 (2009) 216-222
95. Tewodros W., and Kronvall G. M protein gene (emm-type) analysis of group A beta hemolytic streptococci from Ethiopia reveals unique patterns. J Clin Microbiol 43 (2005) 4369-4376
96. Sabharwal H., Michon F., Nelson D., et al. Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. J Infect Dis 193 (2006) 129-135
97. Shet A., Kaplan E.L., Johnson D.R., et al. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development. J Infect Dis 188 (2003) 809-817
98. Batzloff M.R., Hayman W.A., Davies M.R., et al. Protection against group A streptococcus by immunization with J8-diptheria toxoid: contribution of J8-and diptheria toxoid-specific antibodies to protection. J Infect Dis 187 (2003) 1598-1608
99. Batzloff M., Yan H., Davies M., et al. Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection. Indian J Med Res 119 Suppl (2004) 104-107
100. Davidson M., Bulkow L.R., and Gellin B.G. Cardiac mortality in Alaska's indigenous and non-Native residents. Int J Epidemiol 22 (1993) 62-71
101. Schaffer W.L., Galloway J.M., Roman M.J., et al. Prevalence and correlates of rheumatic heart disease in American Indians (The Strong Heart Study). Am J Cardiol 91 (2003) 1379-1382
102. Longstaffe S., Postl B., Kao H., et al. Rheumatic fever in native children in Manitoba. Can Med Assoc J (1982) 127
103. Steer A.C., Kado J., Wilson N., et al. High prevalence of rheumatic heart disease by clinical and echocardiographic screening among children in Fiji. J Heart Valve Dis 18 (2009) 327-335
104. Chun L.T., Reddy D.V., and Yamamoto L.G. Rheumatic fever in children and adolescents in Hawaii. Pediatrics 79 (1987) 549-552
105. Wannamaker L.W., Rammelkamp Jr. C.H., and Denny F.W. Prophylaxis of acute rheumatic fever by treatment of the preceding streptococcal infection with various amounts of depot penicillin. Am J Med 10 (1951) 673-681
106. Manyemba J., and Mayosi B.M. Intramuscular penicillin is more effective than oral penicillin in secondary prevention of rheumatic fever-a systematic review. S Afr Med J 93 (2003) 212-218